Cassava Sciences, Inc. (SAVA): Price and Financial Metrics

Cassava Sciences, Inc. (SAVA): $21.27

0.24 (+1.14%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SAVA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#236 of 363

in industry

SAVA Price/Volume Stats

Current price $21.27 52-week high $32.10
Prev. close $21.03 52-week low $12.32
Day low $20.76 Volume 635,600
Day high $21.59 Avg. volume 761,476
50-day MA $22.01 Dividend yield N/A
200-day MA $21.36 Market Cap 919.84M

SAVA Stock Price Chart Interactive Chart >


Cassava Sciences, Inc. (SAVA) Company Bio


Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.


SAVA Latest News Stream


Event/Time News Detail
Loading, please wait...

SAVA Latest Social Stream


Loading social stream, please wait...

View Full SAVA Social Stream

Latest SAVA News From Around the Web

Below are the latest news stories about CASSAVA SCIENCES INC that investors may wish to consider to help them evaluate SAVA as an investment opportunity.

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Yahoo | December 26, 2023

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 20, 2023

Why Cassava Sciences Stock Zoomed 21% Higher This Week

The company has chosen an offbeat way to keep its investors sweet.

Yahoo | December 15, 2023

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group.

Yahoo | December 13, 2023

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock.

Josh Enomoto on InvestorPlace | December 12, 2023

Read More 'SAVA' Stories Here

SAVA Price Returns

1-mo -3.27%
3-mo -19.40%
6-mo 51.71%
1-year -11.93%
3-year -37.42%
5-year 1,799.11%
YTD -5.51%
2023 -23.80%
2022 -32.40%
2021 540.76%
2020 31.15%
2019 511.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!